Primary immunodeficiencies and susceptibility to parasitic infections

Parasite Immunology

Volumn 28, Issue 11, 2006, Pages 567-575

  Subauste, C S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cryptosporidium; Giardia; Toxoplasma

Indexed keywords

ATAXIA TELANGIECTASIA; BARE LYMPHOCYTE SYNDROME; CHEDIAK HIGASHI SYNDROME; CHRONIC GRANULOMATOUS DISEASE; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; COMPLEMENT DEFICIENCY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DIGEORGE SYNDROME; DISEASE ASSOCIATION; GIARDIA LAMBLIA; GIARDIASIS; HUMAN; HYPERIMMUNOGLOBULINEMIA M; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFECTION SENSITIVITY; PARASITE IMMUNITY; PARASITOSIS; PRIORITY JOURNAL; REVIEW; TOXOPLASMA GONDII; TOXOPLASMOSIS; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA;

DISEASE SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; PARASITIC DISEASES;

CRYPTOSPORIDIUM; GIARDIA; TOXOPLASMA;

EID: 33750052258     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2006.00890.x     Document Type: Review

References (104)

1. http://www.primaryimmune.org/patientsurveypublication.pdf.
2. Buckley RH. Primary immunodeficiency diseases. In Fundamental Immunology, ed. Paul WE. Philadelphia: Lippincott-Raven; 1999: 1427-1453.
3. Cunningham-Rundles C & Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol 2005; 5: 880-892.
4. Notarangelo L, Casanova JL, Fischer A et al. Primary immunodeficiency diseases: An update. J Allergy Clin Immunol 2004; 114: 677-687.
5. Champi C. Primary immunodeficiency disorders in children: Prompt diagnosis can lead to lifesaving treatment. J Pediatr Health Care 2002; 16: 16-21.
6. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004; 22: 625-655.
7. Noguchi M, Yi H, Rosenblatt HM et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73: 147-157.
8. Gilbert E, Anderson J, Cohen F et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067-1069.
9. Russell SM, Tayebi N, Nakayima H et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270: 797-800.
10. Schwarz K, Gauss GH, Ludwig L et al. RAG mutations in human B cell-negative SCID. Science 1996; 274: 97-99.
11. Levy J, Espanol-Boren T, Thomas C et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131: 47-54.
12. Winkelstein JA, Marino MC, Ochs HD et al. The X-linked Hyper-IgM syndrome. Clinical and immunologic features of 79 patients. Medicine 2003; 82: 373-384.
13. Aruffo A, Farrington M, Hollenbaugh D et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 291-300.
14. Grewal IS & Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann Rev Immunol 1998; 16: 111-135.
15. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leuk Biol 2000; 67: 2-17.
16. Ameratunga R, Lederman HM, Sullivan KE et al. Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr 1997; 131: 147-150.
17. Subauste CS, Wessendarp M, Sorensen RU et al. CD40 - CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: Patients with hyper IgM syndrome have a defective type-1 immune response which can be restored by soluble CD40L trimer. J Immunol 1999; 162: 6690-6700.
18. Jain A, Prescott Atkinson T, Lipsky PE et al. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest 1999; 103: 1151-1158.
19. Andrade RM, Wessendarp M & Subauste CS. CD154 activates macrophage anti-microbial activity in the absence of IFN-γ through a TNF-α-dependent mechanism. J Immunol 2003; 171: 6750-6756.
20. Masternak K, Muhlethaler-Mottet A, Villard J et al. Molecular genetics of the bare lymphocyte syndrome. Rev Immunogenet 2000; 2: 267-282.
21. Ochs HD & Notarangelo L. X-linked immunodeficiencies. Curr Allergy Asthma Rep 2004; 4: 339-348.
22. Vetrie D, Vorechovsky I, Sideras P et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361: 226-233.
23. Cunningham-Rundles C. Physiology of IgA and IgA deficiency. J Clin Immunol 2001; 21: 303-309.
24. Hammarstrom L, Vorechovsky I & Webster D. Selective IgA (SIgAD) and common variable immunodeficiency. Clin Exp Immunol 2000; 120: 225-231.
25. Burrows PD & Cooper MD. IgA deficiency. Adv Immunol 1997; 65: 245-276.
26. Cunningham-Rundles C & Bodian C. Common variable immunodeficiency: Clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34-48.
27. Punnonen J, Kainulainen L, Ruuskanen O et al. IL-4 synergizes with IL-10 and anti-CD40 MoAbs to induces B cell differentiation in patients with common variable immunodeficiency. Scand J Immunol 1997; 45: 203-212.
28. + T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry. Clin Exp Immunol 1996; 105: 1099-1103.
29. Farrington M, Grosmaire LS, Nonoyama S et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994; 91: 1099-1103.
30. Buckley RH. Primary cellular immunodeficiencies. J Allergy Clin Immunol 2002; 109: 747-757.
31. Derry JMJ, Ochs HD & Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 78: 635-644.
32. Symons M, Derry JMJ, Karlak B et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42H2, is implicated in actin polymerization. Cell 1996; 84: 723-734.
33. Gatti RA, Boder E, Vinters HV et al. Ataxia-Telangiectasia: an interdisciplinary approach to pathogenesis. Medicine 1991; 70: 99-117.
34. Beamish H, Williams R, Chen P et al. Defect in multiple cell cycle checkpoints in ataxia telangiectasia postirradiation. J Biol Chem 1996; 271: 20486-20493.
35. Xu Y & Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev 1996; 10: 2401-2410.
36. Hong R. The DiGeorge anomaly. Immunodefic Rev 1991; 3: 1-14.
37. Stoller JZ & Epstein JA. Identification of a novel nuclear localization signal in Tbx1 that is deleted in DiGeorge syndrome patients harboring the 1223delC mutation. Hum Mol Genet 2005; 14: 885-892.
38. Stolz W, Graubner U, Gerstmeier J et al. Chediak-Higashi syndrome: approaches in diagnosis and treatment. Curr Probl Dermatol 1989; 18: 93-100.
39. Nagle DL, Karim MA, Woolf EA et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet 1996; 14: 307-311.
40. Heyworth PG, Cross AR & Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003; 15: 578-584.
41. Casanova JL & Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002; 20: 581-620.
42. Doffinger R, Dupuis S, Picard C et al. Inherited disorders of IL-12 and IFN-γ-mediated immunity: a molecular genetics update. Mol Immunol 2001; 38: 903-909.
43. Frank MM. Complement deficiencies. Pediatr Clin North Am 2000; 47: 1339-1354.
44. Faubert G. Immune response to Giardia duodenalis. Clin Microbiol Rev 2000; 13: 35-54.
45. Heyworth MF. Intestinal IgA responses to Giardia muris in mice depleted of helper T lymphocytes and in immunocompetent mice. J Parasitol 1989; 75: 246-251.
46. Stager S & Muller N. Giardia lamblia infections in B-cell-deficient transgenic mice. Infect Immun 1997; 65: 3944-3946.
47. Langford TD, Housley MP, Boes M et al. Central importance of immunoglobulin A in host defences against Giardia spp. Infect Immun 2002; 70: 11-18.
48. Eckmann L. Mucosal defences against Giardia. Parasite Immunol 2003; 25: 259-270.
49. Singer SM & Nash TE. T-cell-dependent control of acute Giardia lamblia infections in mice. Infect Immun 2000; 68: 170-175.
50. Webster ADB. Giardiasis and immunodeficiency diseases. Trans R Soc Trop Med Hyg 1980; 74: 440-443.
51. Lederman HM & Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine 1985; 64: 145-156.
52. Perlmutter DH, Leichtner AM, Goldman H et al. Chronic diarrhea associated with hypogammaglobulinemia and enteropathy in infants and children. Dig Dis Sci 1985; 30: 1149-1155.
53. Ochs HD, Ament ME & Davis SD. Giardiasis with malabsorption in X-linked agammaglobulinemia. New Engl J Med 1972; 287: 341-342.
54. LoGalbo PR, Sampson HA & Buckley RH. Symptomatic giardiasis in three patients with X-linked agammaglobulinemia. J Pediatr 1982; 101: 78-80.
55. Strober W & Sneller MC. IgA deficiency. Ann Allergy 1991; 66: 363-375.
56. Fricker CR & Crabb JH. Water-borne cryptosporidiosis: detection methods and treatment options. Adv Parasitol 1998; 40: 241-278.
57. Waters WR & Harp JA. Cryptosporidium parvum infection in T-cell receptor (TCR)-alpha- and TCR-delta deficient mice. Infect Immun 1996; 64: 1854-1857.
58. Adjei AA, Shrestha AK, Castro M et al. Adoptive transfer of immunity with intraperitoneal lymphocytes in Cryptosporidium parvum-infected severe combined immunodeficient mice. Am J Med Sci 2000; 320: 304-309.
59. Eichelberger MC, Suresh P & Rehg JE. Protection from Cryptosporidium parvum infection by gamma/delta T cells in mice that lack alpha/beta T cells. Comp Med 2000; 50: 270-276.
60. Griffiths JK, Theodos C, Paris M et al. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum. J Clin Microbiol 1988; 36: 2503-2508.
61. Urban JF, Fayer R, Chen SJ et al. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum. J Immunol 1996; 156: 263-268.
62. Lacroix S, Mancassola R, Naciri M et al. Cryptosporidium parvum-specific mucosal immune response in C57BL/6 neonatal and gamma interferon-deficient mice: Role of tumor necrosis factor alpha in protection. Infect Immun 2001; 69: 1635-1642.
63. Leitch GJ & He Q. Reactive nitrogen and oxygen species ameliorate experimental cryptosporidiosis in the neonatal BALB/c mouse model. Infect Immun 1999; 67: 5885-5891.
64. + lymphocytes in gut-associated lymphoid tissue during resolution of infection. J Immunol 1998; 161: 1891-1900.
65. Cosyns M, Tsirkin S, Jones M et al. Requirement for CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun 1998; 66: 603-607.
66. Hayward AR, Cosyns M, Jones M et al. Marrow-derived CD40 positive cells are required for mice to clear a Cryptosporidium parvum infection. Infect Immun 2001; 69: 1630-1634.
67. Chappell CL, Okhuysen PC, Sterling CR et al. Infectivity of Cryptosporidium parvum in healthy adults with pre-existing anti-C. parvum serum immunoglobulin G. Am J Trop Med Hyg 1999; 60: 157-164.
68. Schaefer DA, Auerbach-Dixon BA & Riggs MW. Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis. Infect Immun 2000; 68: 2608-2616.
69. Klein C, Lisowska-Grospierre B, LeDeist F et al. Major histocompatibility complex class II deficiency: Clinical manifestations, immunologic features, and outcome. J Pediatr 1993; 123: 921-928.
70. Saleem MA, Arkwright PD, Davies EG et al. Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child 2000; 83: 356-359.
71. Kocoshis SA, Cibull ML, Davis TE et al. Intestinal and pulmonary cryptosporidiosis in an infant with severe combined immune deficiency. J Pediatr Gastroenterol Nutr 1984; 3: 149-157.
72. Jacyna MR, Parkin J, Goldin R et al. Protracted enteric cryptosporidial infection in selective immunoglobulin A and Saccharomyces opsonin deficiencies. Gut 1990; 31: 714-716.
73. Denkers EY & Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998; 11: 569-588.
74. + T cells in mice. J Immunol 1988; 140: 3943-3946.
75. + T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J Immunol 1992; 149: 175-180.
76. + T cells prevent development of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease. J Immunol 2003; 170: 4254-4259.
77. Hisaeda H, Nagasawa H, Maeda K et al. γδ T cells play an important role in hsp65 expression and in acquiring protective immune responses against infection with Toxoplasma gondii. J Immunol 1995; 154: 244-251.
78. Lepage AC, Buzoni-Gatel D, Bout DT et al. Gut-derived intraepithelial lymphocytes induce long term immunity against Toxoplasma gondii. J Immunol 1998; 161: 4902-4908.
79. + T lymphocytes in IFN-g production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 1991; 146: 286-292.
80. Subauste CS, Chung JY, Do D et al. Preferential activation and expansion of human peripheral blood γδ T cells in response to Toxoplasma gondii in vitro and their cytokine production and cytotoxic activity against T. gondii-infected cells. J Clin Invest 1995; 96: 610-619.
81. Subauste CS, Fuh F, de Waal Malefyt R et al. αβ T cell response to Toxoplasma gondii in previously unexposed individuals. J Immunol 1998; 160: 3403-3411.
82. Hunter CA, Subauste CS, van Cleave VH et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12 and tumor necrosis factor alpha. Infect Immun 1994; 62: 2818-2824.
83. Suzuki Y, Orellana MA, Schreiber RD et al. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science 1988; 240: 516-518.
84. Suzuki Y, Conley FK & Remington JS. Importance of endogenous IFN-γ for prevention of toxoplasmic encephalitis in mice. J Immunol 1989; 143: 2045-2050.
85. Gazzinelli RT, Hieny S, Wynn TA et al. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 1993; 90: 6115-6119.
86. Yap G, Pesin M & Sher A. IL-12 is required for the maintenance of IFN-γ production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J Immunol 2000; 165: 628-631.
87. Sibley LD, Adams LB, Fukutomi Y et al. Tumor necrosis factor-α triggers antitoxoplasmal activity of IFN-γ primed macrophages. J Immunol 1991; 147: 2340-2345.
88. Yap GS, Scharton-Kersten T, Charest H et al. Decreased resistance of TNF receptor p55- and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo. J Immunol 1998; 160: 1340-1345.
89. Kang H, Remington JS & Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase. J Immunol 2000; 164: 2629-2643.
90. Sayles PC, Gibson GW & Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 2000; 68: 1026-1033.
91. Johnson LL, Lanthier P, Hoffman J et al. Vaccination protects B cell-deficient mice against an oral challenge with mildly virulent Toxoplasma gondii. Vaccine 2004; 22: 4054-4061.
92. Reichmann G, Walker W, Villegas EN et al. The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. Infect Immun 2000; 68: 1312-1318.
93. Subauste CS & Wessendarp M. Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: Dendritic cell activation after infection with viable parasites results in CD28 and CD40 Ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-γ. J Immunol 2000; 165: 1498-1505.
94. Andrade RM, Portillo J-AC, Wessendarp M et al. CD40 signaling in macrophages induces anti-microbial activity against an intracellular pathogen independently of IFN-γ and reactive nitrogen intermediates. Infect Immun 2005; 73: 3115-3123.
95. Tsuge I, Matsuoka H & Nakagawa A et al. Necrotizing toxoplasmic encephalitis in a child with the X-linked hyper-IgM syndrome. Eur J Pediatr 1998; 157: 735-737.
96. Leiva LE, Junprasert J, Hollenbaugh D et al. Central nervous system toxoplasmosis with an increased proportion of circulating γδ T cells in a patient with hyper IgM syndrome. J Clin Immunol 1998; 18: 283-290.
97. -/- mice. Infect Immun 2006; 74: 1573-1579.
98. Shachor J, Shneyour A, Radnay J et al. Toxoplasmosis in a patient with common variable immune deficiency. Am J Med Sci 1984; 287: 36-38.
99. Mrusek S, Marx A, Kummerle-Deschner J et al. Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii. Clin Exp Immunol 2004; 137: 578-583.
100. Ottenhoff THM, Kumararatne D & Casanova JL. Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. Immunol Today 1998; 19: 491-494.
101. Dorman SE, Uzel G, Roesler J et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr 1999; 135: 640-643.
102. Janssen R, van Wengen A, Verhard E et al. Divergent role for TNF-α in IFN-γ-induced killing of Toxoplasma gondii and Salmonella typhimurium contributes to selective susceptibility of patients with partial IFN-γ receptor 1 deficiency. J Immunol 2002; 169: 3900-3907.
103. Lieberman LA, Banica M, Reiner SL et al. STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis. J Immunol 2004; 172: 457-463.
104. Gavrielescu LC, Butcher BA, del Rio L et al. STAT1 is essential for antimicrobial effector function but dispensable for gamma interferon production during Toxoplasma gondii infection. Infect Immun 2004; 72: 1257-1264.